Search

Christoph Geisler

from Laramie, WY
Age ~43
Get Report
Also known as:
Christopher Geisler
Phone and address:
1220 Shield St, Laramie, WY 82072
Related to:
Agnes GeislerBernd Geisler
Connected to:
Aaron J Geisler, 37Bartin R Geisler, 45Bill R Geisler, 56Carrol A Geisler, 65Christian J Geisler, 60Darin C Geisler, 54Debbie L Geisler, 65Dennis T Geisler, 78Derek J Geisler, 57Don L Geisler, 96

Christoph Geisler Phones & Addresses

  • 1220 Shield St, Laramie, WY 82072

Resumes

Resumes

Christoph Geisler Photo 1

Chief Research Scientist

View page
Location:
Laramie, WY
Industry:
Biotechnology
Work:
University of Wyoming - Laramie, Wyoming since May 2011
Researcher
Education:
University of Wyoming 2005 - 2011
PhD, Molecular Biology University of Wyoming 2004 - 2005
PhD in Molecular Biology, Chemical Engineering RWTH Aachen 2003 - 2004
Hogeschool Zuyd 1999 - 2003
Bachelor, Chemical Engineering Hogeschool Zuyd (Maastricht, Heerlen, Sittard) 1999 - 2003
Bachelor of Engineering (B.E.), Chemical Engineering
Skills:
Protein Expression
Biochemistry
Cell Culture
Cell Biology
Pcr
Molecular Cloning
Molecular Biology
Viruses
Biotechnology
Cell
Science
Glycoengineering
Glycan Analysis
Research
Western Blotting
Protein Chemistry
Life Sciences
Microbiology
Genetics
Protein Purification
Genomics
Dna
Microscopy
Sds Page
Cell Lines
Genome Sequencing
Transcriptomics
Glycobiology
Glycosylation
Glycomics
Insect Cells
Languages:
Dutch
German
English
Christoph Geisler Photo 2

Founder

View page
Location:
Rawlins, WY
Work:
Theraneutrics
Founder

Publications

Us Patents

Methods Of Using A Bacterial Glcnac-6-P 2'- Epimerase To Promote Sialylation Of Glycoconjugates

View page
US Patent:
20130029413, Jan 31, 2013
Filed:
Jul 27, 2012
Appl. No.:
13/559912
Inventors:
Christoph Geisler - Laramie WY, US
Donald Jarvis - Laramie WY, US
Assignee:
UNIVERSITY OF WYOMING - Laramie WY
International Classification:
C12N 5/10
C12N 1/15
US Classification:
435348, 435419, 43525411, 435325, 435358, 435369, 435350, 435364, 435365, 435367, 435355, 4353723, 435353, 435357, 435352
Abstract:
The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems. The engineered cells can be used to produce glycosylated proteins in virally-infected, transiently-transformed, or stably-transformed host cells, including lepidopteran insects and cultured cell lines derived from , and that can be infected by baculovirus expression vectors.

Lepidopteran Insect N-Acetylglucosaminidase Genes And Their Use In Glycoengineering

View page
US Patent:
20100279415, Nov 4, 2010
Filed:
Dec 12, 2008
Appl. No.:
12/746808
Inventors:
Donald L. Jarvis - Laramie WY, US
Christoph Geisler - Laramie WY, US
International Classification:
C12N 15/85
C12N 15/56
C12N 15/63
C12N 5/07
C12N 9/99
C12N 9/26
US Classification:
435455, 536 232, 4353201, 435348, 435184, 435201
Abstract:
A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed are nucleic acid sequences encoding β-N-acetylglucosaminidases.

Virus-Free Cell Lines And Methods For Obtaining Same

View page
US Patent:
20230059552, Feb 23, 2023
Filed:
Sep 12, 2022
Appl. No.:
17/931200
Inventors:
- Laramie WY, US
Christoph Geisler - Laramie WY, US
Donald Jarvis - Laramie WY, US
International Classification:
C12N 5/07
C12N 15/00
C12N 7/00
Abstract:
The current teachings are directed to novel virus free cells lines derived from virus-contaminated staring material, such as an organism or a cell line. Methods for obtaining virus free cell lines obtained from virus-contaminated starting material are also provided. Exemplary virus free cell lines include: novel cell lines derived from a cell line contaminated with Sf-rhabdovirus, wherein the novel cell lines lack Sf-rhabdovirus; and novel cell lines derived from a cell line contaminated with an alphanodavirus, wherein the novel cell line lacks an alphanodavirus.

Therapeutic Engineered Microbial Cell System And Methods For Treating Hyperuricemia And Gout

View page
US Patent:
20230042430, Feb 9, 2023
Filed:
Jan 8, 2021
Appl. No.:
17/792064
Inventors:
- Laramie WY, US
Christoph Geisler - Laramie WY, US
International Classification:
C12N 1/14
C12N 9/06
C12N 1/20
A61P 19/06
A61K 9/00
Abstract:
The present disclosure relates to engineered microbial cells that have been engineered to include a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered microbial cells of the present disclosure are useful in degrading uric acid inside the engineered microbial cell. The engineered microbial cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered microbial cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout.

Virus-Free Cell Lines And Methods For Obtaining Same

View page
US Patent:
20180355311, Dec 13, 2018
Filed:
Nov 1, 2016
Appl. No.:
15/772476
Inventors:
- Laramie WY, US
Christoph Geisler - Laramie WY, US
Donald Jarvis - Laramie WY, US
Assignee:
Glycobac, LLC - Laramie WY
International Classification:
C12N 5/07
Abstract:
The current teachings are directed to novel virus free cells lines derived from virus-contaminated staring material, such as an organism or a cell line. Methods for obtaining virus free cell lines obtained from virus-contaminated starting material are also provided. Exemplary virus free cell lines include: novel cell lines derived from a cell line contaminated with Sf-rhabdovirus, wherein the novel cell lines lack Sf-rhabdovirus; and novel cell lines derived from a cell line contaminated with an alphanodavirus, wherein the novel cell line lacks an alphanodavirus.

Lepidopteran Insect N-Acetylglucosaminidase Genes And Their Use In Glycoengineering

View page
US Patent:
20150191732, Jul 9, 2015
Filed:
Sep 24, 2014
Appl. No.:
14/495800
Inventors:
- LARAMIE WY, US
CHRISTOPH GEISLER - LARAMIE WY, US
International Classification:
C12N 15/113
C12N 9/24
Abstract:
A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed is a nucleic acid sequence encoding N-acetylglucosaminidase.

Transgenic Insect Cells Comprising A Bacterial Glcnac-6-P 2Prime-Epimerase

View page
US Patent:
20140283154, Sep 18, 2014
Filed:
Mar 14, 2013
Appl. No.:
13/827546
Inventors:
Christoph GEISLER - Laramie WY, US
Donald Jarvis - Laramie WY, US
International Classification:
C12N 15/85
A01K 67/033
US Classification:
800 13, 435348, 800 21
Abstract:
The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial GlcNAc-6-P 2′-epimerase (GNPE), which is capable of converting N-acetyl-D-glucosamine-6-phosphate (GlcNAc-6-P) to N-acetyl-D-mannosamine-6-phosphate (ManNAc-6-P). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors. The invention is also directed to nucleic acids, vectors, and cells comprising nucleic acids encoding polypeptides involved in the synthesis of sialic acid precursors, and cells in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins. The engineered cells can be used to produce glycosylated proteins lepidopteran insects and cultured cell lines derived from , and silkworms, such as , particularly those that can be infected by baculovirus expression vectors.
Control profile
Christoph Geisler from Laramie, WY, age ~43 Get Report